bismuth therapy has shown efficacy against two major gastrointestinal disorders peptic ulcer disease and diarrheain peptic ulcer disease it is as effective as the h2receptor antagonists costs considerably less and offers a lower rate of relapsewhen helicobacter pylori is implicated bismuth acts as an antimicrobial agent suppressing the organism but not eliminating itin recent studies bismuth compounds have been used with conventional antibiotics producing elimination of the organism histological improvement and amelioration of symptoms for periods longer than one yearbismuth subsalicylate has shown modest efficacy in treating travelers diarrhea and acute and chronic diarrhea in children and it is effective prophylactically for travelers diarrheaan epidemic of neurological toxicity was reported in france in the 1970s with prolonged bismuth treatment usually bismuth subgallate and subnitratesuch toxicity has been rare with bismuth subsalicylate and colloidal bismuth subcitratehowever recent studies have demonstrated intestinal absorption of bismuth about 02 of the ingested dose and sequestration of this heavy metal in multiple tissue sites even occurring with conventional dosing over a 6week periodthese findings have inspired recommendations that treatment periods with any bismuthcontaining compound should last no longer than 68 weeks followed by 8week bismuthfree intervals